PDGFRA and myeloid sarcoma: Since imatinib has been shown to block PDGFR-α signaling and reduce both cerebrovascular permeability and hemorrhagic complications in two different stroke models [9], [10], we aimed to explore a possible beneficial effect of imatinib in the MS model.